LAMITRODE SPINAL CORD STIMULATION LEADS

K033429 · Advanced Neuromodulation Systems · GZB · Dec 4, 2003 · Neurology

Device Facts

Record IDK033429
Device NameLAMITRODE SPINAL CORD STIMULATION LEADS
ApplicantAdvanced Neuromodulation Systems
Product CodeGZB · Neurology
Decision DateDec 4, 2003
DecisionSESE
Submission TypeSpecial
Regulation21 CFR 882.5880
Device ClassClass 2
AttributesTherapeutic

Intended Use

Advanced Neuromodulation Systems Lamitrode Spinal Cord Stimulation Leads are indicated for the treatment of chronic pain of the trunk and limbs, either as the sole mitigating agent, or as an adjunct to other modes of therapy used in a multidisciplinary approach and are intended to be used with Advanced Neuromodulation Systems extensions and/or, receivers, transmitters, and antennae.

Device Story

Lamitrode Spinal Cord Stimulation Leads (Models 3245/3289) are implantable electrodes used for chronic pain management. Leads deliver electrical stimulation to spinal cord tissue to modulate pain signals. Used in conjunction with Advanced Neuromodulation Systems (ANS) extensions, receivers, transmitters, and antennae. Operated by physicians during surgical implantation; system provides therapeutic electrical pulses to patients. Benefits include chronic pain relief for trunk and limbs.

Clinical Evidence

No clinical data provided; substantial equivalence based on technological characteristics and intended use.

Technological Characteristics

Implantable spinal cord stimulation leads; models 3245 (Lamitrode 44C) and 3289 (Lamitrode 88C). Class II device (21 CFR 882.5880). Product code GZB.

Indications for Use

Indicated for treatment of chronic pain of the trunk and limbs in patients requiring spinal cord stimulation, either as a sole therapy or as an adjunct in a multidisciplinary approach.

Regulatory Classification

Identification

An implanted spinal cord stimulator for pain relief is a device that is used to stimulate electrically a patient's spinal cord to relieve severe intractable pain. The stimulator consists of an implanted receiver with electrodes that are placed on the patient's spinal cord and an external transmitter for transmitting the stimulating pulses across the patient's skin to the implanted receiver.

Related Devices

Submission Summary (Full Text)

{0}------------------------------------------------ Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized eagle with three bars representing its wings, and the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged in a circular fashion around the eagle. The text is in all caps and appears to be in a sans-serif font. Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 DEC - 4 2003 Ms. Danielle Alarcon Regulatory Affairs Specialist Advanced Neuromodulation Systems 6501 Windcrest Drive, Suite 100 Plano, Texas 75024 Re: K033429 Device Name: C-Series Lamitrode Spinal Cord Stimulation Leads, Model Numbers 3245 (Lamitrode 44C) and 3289 (Lamitrode 88C) Regulation Number: 21 CFR 882.5880 Regulation Name: Implanted spinal cord stimulator for pain relief Regulatory Class: Class II Product Code: GZB Dated: October 27, 2003 Received: November 4, 2003 Dear Ms. Alarcon: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice {1}------------------------------------------------ Page 2 - Ms. Danielle Alarcon requirements as sct forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4648. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers. International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html Sincerely yours. R. Mark N. Milliken Celia M. Witten, M.D., Ph.D. Director Division of General, Restorative, and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {2}------------------------------------------------ 510(k) Number (if known): K033429 Device Name: Lamitrode Leads Indications For Use: Advanced Neuromodulation Systems Lamitrode Spinal Cord Stimulation Leads are indicated for the treatment of chronic pain of the trunk and limbs, either as the sole mitigating agent, or as an adjunct to other modes of therapy used in a multidisciplinary approach and are intended to be used with Advanced Neuromodulation Systems extensions and/or, receivers, transmitters, and antennae. ## (PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, office of Device Evaluation (ODE) | | <i>for</i> Mark N. Millman | |--------------------------|----------------------------------------------------| | Division | | | Division | Restorative | | and Newrological Devices | | | 510(k) number | K033429 | | Prescription Use | <span style="text-decoration: underline;">✓</span> | | (Per 21 CFR 801.109) | | Or Over-The-Counter Use ____
Innolitics
510(k) Summary
Decision Summary
Classification Order
Enter a record ID and click Load to view the document.
100%